RT Journal Article SR Electronic T1 Use of an ELISPOT interferon-gamma release assay for screening of end-stage renal failure contacts in haemodialysis centres JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3058 VO 44 IS Suppl 58 A1 Cynthia Chee A1 Leo Lim A1 Chwee-Kim Koh A1 Kyi-Win KhinMar A1 Suay-Hong Gan A1 Yee-Tang Wang YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P3058.abstract AB End-stage renal failure (ESRF) is a risk factor for progression of latent TB infection to active TB disease. Reports in the literature thus far indicate superior sensitivity of the whole blood ELISA interferon-gamma release assay (IGRA) over the tuberculin skin test in this risk group, whereas data pertaining to the ELISPOT IGRA are relatively lacking.We report Singapore's experience with the T-SPOT.TB assay for screening of ESRF contacts exposed to infectious index cases in haemodialysis centres.From January 2007 to November 2013, a total of 488 ESRF contacts were screened. Five active TB cases were detected at screening (yield 1%): of these, four tested T-SPOT.TB positive and one had a borderline result. Of the remaining 483 contacts, 360 were tested once with the T-SPOT.TB, while 123 who tested negative within the window period underwent repeat testing after this period. Altogether, 142 (29.4%) tested positive, 308 (63.8%) tested negative, and 30 (6.2%) had borderline results. There were 3 (0.5% of 611) failed tests.132 of 156 contacts who were advised preventive therapy (PT) commenced treatment. To date, 85 completed PT; 35 did not complete PT (of whom 6 died); and 12 are still receiving PT.Three contacts with positive T-SPOT.TB (one of whom completed PT), and one contact with negative T-SPOT.TB subsequently developed active TB.The positive and negative predictive values of the T-SPOT.TB for progression to active TB are 3.8% and 99.7% respectively in our population of haemodialysis centre contacts with ESRF.